Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Hypoxic-ischaemic encephalopathy24.04.06.021; 22.02.02.011; 17.13.02.0060.002024%Not Available
Sensitisation08.01.05.009; 10.02.01.012--Not Available
Drug-induced liver injury12.03.01.044; 09.01.07.0230.006071%Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.001012%Not Available
Hepatocellular carcinoma16.07.02.005; 09.04.02.0100.006577%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.002024%
Immune-mediated adverse reaction10.02.01.0440.001012%Not Available
Liver function test increased13.03.04.031--Not Available
Persistent depressive disorder19.15.01.006--Not Available
Mitral valve stenosis02.07.01.0090.001012%Not Available
Neonatal asphyxia22.11.02.006; 18.04.15.0050.002024%Not Available
Neonatal respiratory failure22.11.02.011; 18.04.17.0030.002024%Not Available
Pulmonary valve stenosis02.07.04.0050.001012%Not Available
Renal failure neonatal20.01.03.024; 18.04.01.0190.002024%Not Available
Small for dates baby18.04.02.0020.004048%Not Available
Soliloquy19.05.01.0210.001518%Not Available
Vitritis06.04.06.0130.001012%Not Available
Multiple-drug resistance08.06.01.0320.001012%Not Available
Bone infarction24.04.05.011; 15.02.04.0310.001012%Not Available
Mitochondrial cytopathy14.11.02.0080.002024%Not Available
Foetal cardiac disorder02.11.01.013; 18.03.02.0130.001012%Not Available
Carnitine deficiency14.08.04.0220.003542%Not Available
Necrotising retinitis24.04.10.006; 06.04.06.0120.001518%Not Available
Distributive shock24.06.02.0220.001012%Not Available
Infantile apnoea22.11.02.004; 18.04.15.0030.002024%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.009--Not Available
Hyperintensity in brain deep nuclei17.11.01.0210.001012%Not Available
Hypophosphataemic osteomalacia15.02.03.019; 16.32.01.011; 14.04.04.0180.002024%Not Available
Immune reconstitution inflammatory syndrome associated Kaposi's sarcoma16.33.02.003; 11.05.17.012; 10.02.01.081; 08.06.02.0250.001012%Not Available
The 12th Page    First    Pre   12 13    Next   Last    Total 13 Pages